Metrics to compare | VALX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVALXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −8.8x | −0.3x | |
PEG Ratio | −0.01 | −0.13 | 0.00 | |
Price/Book | 0.7x | 4.1x | 2.6x | |
Price / LTM Sales | 65.2x | 7.8x | 3.1x | |
Upside (Analyst Target) | - | 184.1% | 47.6% | |
Fair Value Upside | Unlock | −13.0% | 5.6% | Unlock |
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the development of BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment of SARS-CoV2 infection; and CLX001, a peptide in a nanoparticle formulation for the treatment of triple negative breast cancer. The company was founded in 2006 and is based in London, the United Kingdom.